| 摘要 |
The present invention provides methods of treating fibrotic diseases, including pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis from a known etiology, liver fibrosis, cardiac fibrosis, and renal fibrosis. The methods generally involve administering to an individual with a fibrotic disease (i) pirfenidone, a pirfenidone analog or a Type II interferon receptor agonist and (ii) a TGF-ß antagonist or an endothelin receptor antagonist concurrently, in an amount effective to ameliorate the clinical course of the disease. The invention also provides a method of treating a fibrotic disorder by administering to an individual (i) pirfenidone, a pirfenidone analog or a Type II interferon receptor agonist and (ii) a TGF-ß antagonist or an endothelin receptor antagonist in synergistically effective amounts to ameliorate the clinical course of the disease. |
